Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect on Seizures and Behavioral Symptoms of Radiprodil in Patients With Tuberous Sclerosis Complex (TSC) or Focal Cortical Dysplasia (FCD) Type II

NCT06392009 is registered in ClinicalTrials.gov with GRIN Therapeutics, Inc. as lead sponsor.

NCT NCT06392009
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06392009 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect on Seizures and Behavioral Symptoms of Radiprodil in Patients With Tuberous Sclerosis Complex (TSC) or Focal Cortical Dysplasia (FCD) Type II
Lead sponsor
GRIN Therapeutics, Inc.
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
July 10, 2024
Completion date
June 30, 2028
Enrollment
30 (estimated)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

focal cortical dysplasia, tuberous sclerosis complex